Medical School

  • University of Michigan Medical School , 2006 , Ann Arbor , MI


  • Comer Children's Hospital & University of Chicago Medical Center , 2009 , Chicago , IL


  • Boston Children's Hospital , 2012 , Boston , MA


  • American Board of Pediatrics, General Pediatrics
  • American Board of Allergy and Immunology


Publications powered by Harvard Catalyst Profiles

  1. A homozygous stop-gain variant in ARHGAP42 is associated with childhood interstitial lung disease, systemic hypertension, and immunological findings. PLoS Genet. 2021 07; 17(7):e1009639. View abstract
  2. Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. J Allergy Clin Immunol Pract. 2020 10; 8(9S):S16-S116. View abstract
  3. Acetaminophen Inhibits the Neutrophil Oxidative Burst: Implications for Diagnostic Testing. J Allergy Clin Immunol Pract. 2020 Nov - Dec; 8(10):3543-3548. View abstract
  4. Expanded genetic insight and clinical experience of DNMT1-complex disorder. Neurol Genet. 2020 Aug; 6(4):e456. View abstract
  5. An emerging role for endothelial barrier support therapy for congenital disorders of glycosylation. J Inherit Metab Dis. 2020 07; 43(4):880-890. View abstract
  6. Reply. J Allergy Clin Immunol Pract. 2019 04; 7(4):1376-1377. View abstract
  7. Acquired Cold-Induced Urticaria in Pediatric Patients: A 22-Year Experience in a Tertiary Care Center (1996-2017). J Allergy Clin Immunol Pract. 2019 03; 7(3):1024-1031.e3. View abstract
  8. Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab. J Allergy Clin Immunol Pract. 2019 02; 7(2):451-461.e7. View abstract
  9. A twenty-two-year experience with Hymenoptera venom immunotherapy in a US pediatric tertiary care center 1996-2018. Ann Allergy Asthma Immunol. 2018 12; 121(6):722-728.e1. View abstract
  10. Patients with CD3G mutations reveal a role for human CD3? in Treg diversity and suppressive function. Blood. 2018 05 24; 131(21):2335-2344. View abstract
  11. Successful rapid oral clindamycin desensitization in a pediatric patient. J Allergy Clin Immunol Pract. 2018 Nov - Dec; 6(6):2141-2142. View abstract
  12. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J Clin Invest. 2016 11 01; 126(11):4389. View abstract
  13. The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions. Curr Allergy Asthma Rep. 2016 Apr; 16(4):25. View abstract
  14. Recurrent viral infections associated with a homozygous CORO1A mutation that disrupts oligomerization and cytoskeletal association. J Allergy Clin Immunol. 2016 Mar; 137(3):879-88.e2. View abstract
  15. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J Clin Invest. 2015 Nov 02; 125(11):4135-48. View abstract
  16. A novel mutation in ORAI1 presenting with combined immunodeficiency and residual T-cell function. J Allergy Clin Immunol. 2015 Aug; 136(2):479-482.e1. View abstract
  17. Leucine-rich repeat containing 8A (LRRC8A) is essential for T lymphocyte development and function. J Exp Med. 2014 May 05; 211(5):929-42. View abstract
  18. Successful desensitization to brentuximab vedotin after anaphylaxis. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):e73-5. View abstract
  19. Disruption of MHC class II-restricted antigen presentation by vaccinia virus. J Immunol. 2005 Nov 15; 175(10):6481-8. View abstract
  20. Enhanced production of IL-10 by dendritic cells deficient in CIITA. J Immunol. 2005 Feb 01; 174(3):1222-9. View abstract
  21. Cathepsin E: a novel target for regulation by class II transactivator. J Immunol. 2004 May 01; 172(9):5528-34. View abstract
  22. Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity. J Biol Chem. 2001 Jun 01; 276(22):19089-93. View abstract
  23. Effective antigen-specific immunotherapy in the marmoset model of multiple sclerosis. J Immunol. 2001 Feb 01; 166(3):2116-21. View abstract
  24. Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line. Urology. 1999 Oct; 54(4):746-52. View abstract
  25. Carboplatin-induced cell death in model prostate cancer systems. Anticancer Res. 1998 Nov-Dec; 18(6A):4475-82. View abstract
  26. The effect of castanospermine on the metastatic properties of prostate cancer cells. Anticancer Res. 1997 Sep-Oct; 17(5A):3659-63. View abstract
  27. Differential recognition of microfilarial chitinase, a transmission-blocking vaccine candidate antigen, by sera from patients with Brugian and Bancroftian filariasis. Am J Trop Med Hyg. 1995 Sep; 53(3):289-94. View abstract